iMORE+ Study: A Multi-Omics Cohort Study of Major Depressive Disorder (iMORE+)
30 juillet 2026 mis à jour par: Shanghai Mental Health Center
iMORE+ Study: An Enhanced Prospective Observational Cohort Study of Major Depressive Disorder Integrating Longitudinal Clinical Characterization and Multi-Omics Profiling
Major depressive disorder (MDD) is a common mental health condition characterized by substantial clinical heterogeneity and variability in treatment response. Current diagnosis and treatment selection for MDD mainly rely on clinical assessments, and reliable biological markers that can support diagnosis, predict antidepressant treatment response, guide personalized treatment, and improve understanding of disease mechanisms remain limited.
The goal of this prospective observational cohort study is to develop and optimize multi-omics-based models for MDD diagnosis and antidepressant treatment response prediction using longitudinal clinical characteristics and biological data collected from an independent prospective cohort. The study also aims to evaluate the generalizability and predictive performance of existing multi-omics-based models in this independent cohort of participants aged 14-45 years.
The main questions it aims to answer are:
Can integrated clinical and multi-omics features identify biomarkers and develop predictive models for MDD diagnosis and antidepressant treatment response? Can existing multi-omics-based models for MDD diagnosis and treatment response prediction be replicated and validated in an independent prospective cohort?
Participants with MDD and healthy controls will undergo standardized clinical assessments, longitudinal follow-up, and biological sample collection for multi-omics profiling. Clinical and multi-omics data will be integrated to identify biomarkers, develop and validate predictive models for MDD diagnosis, antidepressant treatment response, and long-term outcomes, and explore biological pathways and potential therapeutic targets associated with MDD.
The study is expected to improve understanding of the biological heterogeneity of MDD and contribute to the development of objective approaches for diagnosis, treatment response prediction, personalized care, and future therapeutic discovery.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Type d'étude
Observationnel
Inscription (Estimé)
150
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Shen He
- Numéro de téléphone: +86 18817314682
- E-mail: shenhe0204@126.com
Lieux d'étude
-
-
-
Shanghai, Chine, 200030
- Shanghai Mental Health Center
-
Contact:
- Shen He, Dr.
- Numéro de téléphone: 02134773128
- E-mail: shenhe0204@126.com
-
Contact:
- He
- E-mail: shenhe@smhc.org.cn
-
Chercheur principal:
- Shen He, Dr.
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
Accepte les volontaires sains
Oui
Méthode d'échantillonnage
Échantillon non probabiliste
Population étudiée
This study enrolls participants aged 14-45 years from outpatient and inpatient psychiatric settings, comprising two cohorts: participants meeting DSM-5 criteria for major depressive disorder (MDD) and demographically matched healthy controls (HCs) without current or lifetime major psychiatric disorders.
MDD participants are recruited during an active depressive episode with baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥24 and 17-item Hamilton Depression Rating Scale (HAMD-17) score ≥18.
HC participants are frequency-matched to the MDD cohort by age and sex distribution.
La description
Inclusion Criteria:
General criteria:
- Participants aged 14-45 years.
- Participants are able to understand the study procedures and provide written informed consent. For participants younger than 18 years, both the participant and their legal guardian must provide consent.
Major Depressive Disorder (MDD) cohort:
- Meet DSM-5 criteria for major depressive disorder (single or recurrent episode).
- Have a baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥24 and 17-item Hamilton Depression Rating Scale (HAMD-17) score ≥18.
Healthy Control (HC) cohort:
- Healthy participants without a current or lifetime diagnosis of major psychiatric disorders.
Exclusion Criteria:
For all participants:
- Severe or unstable medical conditions, pregnancy or breastfeeding, or other conditions considered unsuitable for study participation.
For the MDD cohort:
- Current or lifetime diagnosis of other major psychiatric disorders, including schizophrenia spectrum disorders, schizoaffective disorder, or bipolar disorder.
- Substance use disorder within 12 months prior to screening.
- Depression secondary to medical or neurological conditions.
- Regular antidepressant treatment within 2 weeks prior to enrollment.
- Electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), vagus nerve stimulation (VNS), or immunosuppressive therapy during the current depressive episode.
- Current active suicidal plan or recent suicidal behavior considered unsuitable for participation.
For the HC cohort:
- Current or lifetime diagnosis of any psychiatric disorder.
- Significant depressive, anxiety, manic, or psychotic symptoms.
- Previous treatment with antidepressants, antipsychotics, or mood stabilizers.
- Significant family history of major psychiatric disorders.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Major Depressive Disorder (MDD) Cohort
Participants with major depressive disorder (MDD) aged 14-45 years will be enrolled in this cohort.
Participants will undergo standardized clinical assessments, biological sample collection, and longitudinal follow-up during antidepressant treatment.
Clinical data and biological samples will be collected at predefined time points for multi-omics profiling, including genomics, transcriptomics (bulk and single-cell), proteomics, metabolomics, immune cell phenotyping, and gut microbiome analyses, among others.
|
|
Healthy Control (HC) Cohort
Healthy participants aged 14-45 years will be enrolled as a comparison cohort.
Participants will undergo baseline clinical assessments and biological sample collection for comparison with individuals with major depressive disorder.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 8
Délai: Baseline to Week 8
|
The primary outcome is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to Week 8 after antidepressant treatment.
The MADRS is a clinician-rated scale assessing depressive symptom severity.
The total score ranges from 0 to 60, with higher scores indicating greater depressive symptom severity (worse outcome).
Change in MADRS total score from baseline to Week 8 will be assessed as the primary clinical endpoint.
|
Baseline to Week 8
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Antidepressant Treatment Response Rate Based on Montgomery-Åsberg Depression Rating Scale (MADRS) at Week 8
Délai: Baseline to Week 8
|
Treatment response is defined as a ≥50% reduction from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 8.
The MADRS score ranges from 0 to 60, with higher scores indicating greater depressive symptom severity (worse outcome).
The outcome measure is the percentage of participants achieving treatment response.
|
Baseline to Week 8
|
|
17-item Hamilton Depression Rating Scale (HAMD-17)-Defined Treatment Response at Week 8
Délai: Baseline to Week 8
|
Treatment response is defined as a ≥50% reduction from baseline in 17-item Hamilton Depression Rating Scale (HAMD-17) total score at Week 8.
The HAMD-17 total score ranges from 0 to 52, with higher scores indicating greater depressive symptom severity (worse outcome).
The outcome measure is the percentage of participants achieving treatment response.
|
Baseline to Week 8
|
|
Montgomery-Åsberg Depression Rating Scale (MADRS)-Defined Antidepressant Treatment Remission at Week 8
Délai: Baseline to Week 8
|
Remission is defined as a total score ≤10 on the Montgomery-Åsberg Depression Rating Scale (MADRS) at Week 8.
The MADRS score ranges from 0 to 60, with higher scores indicating greater depressive symptom severity (worse outcome).
The outcome measure is the percentage of participants achieving remission.
|
Baseline to Week 8
|
|
17-item Hamilton Depression Rating Scale (HAMD-17)-Defined Antidepressant Treatment Remission at Week 8
Délai: Baseline to Week 8
|
Remission is defined as a total score ≤7 on the 17-item Hamilton Depression Rating Scale (HAMD-17) at Week 8.
The HAMD-17 score ranges from 0 to 52, with higher scores indicating greater depressive symptom severity (worse outcome).
The outcome measure is the percentage of participants achieving remission.
|
Baseline to Week 8
|
|
Change in Hamilton Anxiety Rating Scale (HAMA) Score From Baseline to Week 8
Délai: Baseline to Week 8
|
The Hamilton Anxiety Rating Scale (HAMA) is a clinician-rated scale assessing anxiety symptom severity.
The total score ranges from 0 to 56, with higher scores indicating greater anxiety severity (worse outcome).
|
Baseline to Week 8
|
|
Change in Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN) Score From Baseline to Week 8
Délai: Baseline to Week 8
|
The Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN) assesses biological rhythm disruption.
The total score range from 18 to 72, with higher scores indicating greater circadian rhythm disturbance (worse outcome).
|
Baseline to Week 8
|
|
Change in Clinical Global Impression-Severity (CGI-S) Score From Baseline to Week 8
Délai: Baseline to Week 8
|
The Clinical Global Impression-Severity (CGI-S) scale assesses overall illness severity as rated by the clinician.
Scores range from 1 to 7, with higher scores indicating greater illness severity (worse outcome).
Change in CGI-S score from baseline to Week 8 will be assessed.
|
Baseline to Week 8
|
|
Clinical Global Impression-Improvement (CGI-I) Score at Week 8
Délai: Baseline to Week 8
|
The Clinical Global Impression-Improvement (CGI-I) scale assesses overall clinical improvement after treatment.
Scores range from 1 to 7, with lower scores indicating greater improvement (better outcome).
|
Baseline to Week 8
|
|
Number of Participants With Suicidal Ideation or Suicidal Behavior Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Week 8
Délai: Baseline to Week 8
|
Number of participants with suicidal ideation or suicidal behavior assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
|
Baseline to Week 8
|
|
Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score From Baseline to Week 8
Délai: Baseline to Week 8
|
The Snaith-Hamilton Pleasure Scale (SHAPS) is a self-reported scale assessing anhedonia.
The total score ranges from 0 to 14, with higher scores indicating greater anhedonia severity (worse outcome).
Change in SHAPS score from baseline to Week 8 will be assessed.
|
Baseline to Week 8
|
|
Change in Sheehan Disability Scale (SDS) Score From Baseline to Week 8
Délai: Baseline to Week 8
|
The Sheehan Disability Scale (SDS) is a self-reported scale assessing functional impairment in work/school, social life, and family life.
The total score ranges from 0 to 30, with higher scores indicating greater functional impairment (worse outcome).
Change in SDS score from baseline to Week 8 will be assessed.
|
Baseline to Week 8
|
|
Incidence of Depressive Relapse During 1-Year Follow-up
Délai: Baseline to 1 year
|
Depressive relapse during 1-year follow-up will be assessed according to DSM-5 criteria and clinically relevant clinical events.
The number and percentage of participants experiencing relapse will be reported.
|
Baseline to 1 year
|
|
Longitudinal Trajectory of Montgomery-Åsberg Depression Rating Scale (MADRS) Score Over 1-Year Follow-up
Délai: Baseline, Week 2, Week 4, Week 8, Month 3, Month 6, and Year 1
|
The Montgomery-Åsberg Depression Rating Scale (MADRS) assesses depressive symptom severity.
Total scores range from 0 to 60, with higher scores indicating greater depressive symptom severity (worse outcome).
Longitudinal changes in MADRS scores from baseline will be assessed at predefined assessment time points (Baseline, Week 2, Week 4, Week 8, Month 3, Month 6, and Year 1) to characterize trajectories of depressive symptom change over the 1-year follow-up period.
|
Baseline, Week 2, Week 4, Week 8, Month 3, Month 6, and Year 1
|
|
Longitudinal Trajectory of Sheehan Disability Scale (SDS) Score Over 1-Year Follow-up
Délai: Baseline, Week 8, Month 6, and Year 1
|
The Sheehan Disability Scale (SDS) assesses functional impairment in work/school, social life, and family life.
The total score ranges from 0 to 30, with higher scores indicating greater functional impairment (worse outcome).
Changes in SDS scores from baseline will be assessed at Week 8, Month 6, and Year 1 to characterize trajectories of functional recovery over the 1-year follow-up period.
|
Baseline, Week 8, Month 6, and Year 1
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Area Under the Receiver Operating Characteristic Curve (AUROC) of Multi-Omics-Based Models for Discriminating Major Depressive Disorder From Healthy Controls
Délai: Baseline
|
A multivariable model integrating clinical characteristics and multi-omics data, including immune profiling (CyTOF and cytokine profiling), genomics, epigenomics, bulk transcriptomics, single-cell transcriptomics, proteomics, metabolomics, and microbiome profiling, will be developed to discriminate participants with major depressive disorder from healthy controls.
Model discrimination performance will be primarily assessed by the area under the receiver operating characteristic curve (AUROC).
Sensitivity, specificity, and predictive accuracy will be reported as supportive metrics.
|
Baseline
|
|
Area Under the Receiver Operating Characteristic Curve (AUROC) of Multi-Omics-Based Models for Predicting MADRS-Defined Antidepressant Treatment Response at Week 8
Délai: Baseline to Week 8 (baseline predictors and Week 8 treatment response assessment)
|
A multivariable model integrating baseline clinical characteristics and multi-omics data, including immune profiling (CyTOF and cytokine profiling), genomics, epigenomics, bulk transcriptomics, single-cell transcriptomics, proteomics, metabolomics, and microbiome profiling, will be developed to predict antidepressant treatment response at Week 8. Treatment response will be defined as a ≥50% reduction from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 8. Model predictive performance will be primarily assessed by the area under the receiver operating characteristic curve (AUROC), with internal validation performed using bootstrap resampling.
Calibration, sensitivity, specificity, and predictive accuracy will be reported as supportive metrics.
|
Baseline to Week 8 (baseline predictors and Week 8 treatment response assessment)
|
|
Area Under the Receiver Operating Characteristic Curve (AUROC) of Multi-Omics-Based Models Integrating Baseline Profiles and Week 4 Molecular Changes for Predicting MADRS-Defined Antidepressant Treatment Response at Week 8
Délai: Baseline to Week 8
|
A longitudinal multivariable model integrating baseline clinical characteristics, baseline multi-omics profiles, and multi-omics changes from baseline to Week 4 will be developed to predict MADRS-defined antidepressant treatment response at Week 8. Treatment response will be defined as a ≥50% reduction from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 8. Multi-omics data will include immune profiling (CyTOF and cytokine profiling), genomics, epigenomics, bulk transcriptomics, single-cell transcriptomics, proteomics, metabolomics, and microbiome profiling.
Model predictive performance will be primarily assessed by the area under the receiver operating characteristic curve (AUROC), with internal validation performed using bootstrap resampling.
Calibration, sensitivity, specificity, and predictive accuracy will be reported as supportive metrics.
|
Baseline to Week 8
|
|
Number of Significantly Altered Multi-Omics Features From Baseline to Week 8 of Antidepressant Treatment
Délai: Baseline to Week 8
|
Longitudinal changes in multi-omics profiles from baseline to Week 8 will be analyzed to identify molecular features significantly altered following antidepressant treatment.
Multi-omics analyses will include immune profiling (CyTOF and cytokine profiling), genomics, epigenomics, bulk transcriptomics, single-cell transcriptomics, proteomics, metabolomics, and microbiome profiling.
Statistically significant features will be identified based on predefined statistical thresholds, and the number of significantly altered features will be reported.
|
Baseline to Week 8
|
|
Predictive Performance of Multi-Omics-Based Models for Predicting One-Year Sheehan Disability Scale (SDS) Score
Délai: Baseline to Year 1
|
A multivariable model integrating baseline clinical characteristics and multi-omics data will be developed to predict the Sheehan Disability Scale (SDS) total score at 1-year follow-up.
The SDS is a self-reported scale assessing functional impairment.
The SDS total score ranges from 0 to 30, with higher scores indicating greater functional impairment (worse outcome).
Model predictive performance will be assessed using predefined regression metrics, including coefficient of determination (R²), root mean square error (RMSE), and mean absolute error (MAE).
Internal validation will be performed using bootstrap resampling.
|
Baseline to Year 1
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Shen He, Shanghai Mental Health Center
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 septembre 2027
Achèvement primaire (Estimé)
31 décembre 2027
Achèvement de l'étude (Estimé)
1 février 2028
Dates d'inscription aux études
Première soumission
20 juillet 2026
Première soumission répondant aux critères de contrôle qualité
26 juillet 2026
Première publication (Réel)
29 juillet 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
3 août 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
30 juillet 2026
Dernière vérification
1 juillet 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- iMORE PLus-MDD-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
INDÉCIS
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .